Genprex Inc. logo

Genprex (GNPX) stock

GNPX · Genprex Inc. · NASDAQ

Website
Market cap
$2.2M
Shares out
1.3M

Why is GNPX stock moving today?

PRago · 21h ago
Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer

Data Presented at the 2026 EORTC-NCI-AACR Symposium Show TROP2 Levels May Help Predict Which Tumors Respond to Reqorsa® and Modulating TROP2 May Enhance EfficacyAUSTIN, Texas, Nov. 19, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today announced new preclinical data identifying low TROP2 expression as a potential predictive biomarker of primary resistance to its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product, in non-small cell lung cancer (NSCLC). The findings w

All GNPX news

Are insiders buying or selling GNPX?

No GNPX insider has reported a purchase or sale in the last 90 days. The last trade on file: Brent M Longnecker sold $22, reported on Apr 15, 2026.

GNPX insider trades

Financial highlights

Full financials
Net income, TTM
-$16.94M
Cash
$15.35M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

Latest news

25 items

GNPX rankings

News · 26 weeks29+350%
2026-05-24: 22026-05-31: 12026-06-07: 12026-06-14: 22026-06-21: 32026-06-28: 02026-07-05: 02026-07-12: 12026-07-19: 02026-07-26: 12026-08-02: 32026-08-09: 12026-08-16: 22026-08-23: 02026-08-30: 02026-09-06: 12026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 22026-10-25: 22026-11-01: 42026-11-08: 22026-11-15: 1
2026-05-242026-11-15
Mix1290d
  • Other7(58%)
  • SEC Filings5(42%)
Activity · 52 weeks7146 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Genprex Inc. (GNPX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 11 wire items for GNPX, including 6 press releases and news items and 5 SEC filings. The most recent was published Nov 19, 2026.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

GNPX FAQ

8 questions
  • What does Genprex Inc. do?
    Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell...
  • Is GNPX profitable?
    No. Genprex Inc. reported a net loss of $16.94M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does GNPX have?
    Genprex Inc. reported $15.35M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does GNPX stock trade?
    Genprex Inc. (GNPX) is listed on NASDAQ.
  • What sector and industry is GNPX in?
    Genprex Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Genprex Inc. go public?
    Genprex Inc. (GNPX) completed its IPO in 2018.
  • What companies are similar to GNPX?
    Notable peers in the same industry include MGTX (MeiraGTx Holdings plc), NTLA (Intellia Therapeutics Inc.), RCKT (Rocket Pharmaceuticals Inc.), SRPT (Sarepta Therapeutics Inc.), SLDB (Solid Biosciences Inc.). Compare GNPX side-by-side with any of them on Quantisnow.
  • How can I track GNPX on Quantisnow?
    Quantisnow aggregates Genprex Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GNPX to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change